Loading
No insider purchase over the last 90 days. The latest, by SARITABEN VALLABHBHAI SAVANI, was filed 04 Dec 2025.
Par Drugs And Chemicals Limited: what insiders have been doing
Par Drugs And Chemicals Limited, classified in the Chemicals sector, is a listed company. Its insiders report their share dealings to SEBI (PIT + SAST). From 26 October 2025 to 26 October 2026, the disclosure feed for Par Drugs And Chemicals Limited logged 1 filing by 1 insider.
Every open-market trade in the period is a purchase: 1 purchase worth €4,257, from 1 insider, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €4,257 from Saritaben Vallabhbhai Savani, disclosed on 4 December 2025. Among those who bought: 1 major shareholder.
The most recent open-market purchase was published on 4 December 2025, 326 days ago.
Across the 1,986 companies tracked on its exchange, the median is 4 filings; at 1 filing, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 31 purchases and 2 sales.
In the same sector, recent insider purchases at Culp Inc also feature in our signals. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€87,192
31 ops. · all time
Sell Volume
€246,313
2 ops. · all time
Who traded when
BuySaleSaritaben Vallabhbhai Savani1 buy
Since the insiders bought
- -5.5%Entry ₹96.84 · Close at T+90 ₹91.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,664 of 26,320 companies
74.0
score / 100
Value84
Quality65
FCF yld11%
Earn yld10%
EV/EBITDA6.2x
ROE12%
Gross mgn30%
Net mgn13%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹117.10
Analyst consensus
Income statement
Revenue₹1B
Gross profit₹304.2M30% margin
EBITDA₹210M20% margin
Net income₹131.1M13.3% margin
Valuation
PER (trailing)11.0x
P/Book1.3x
Beta0.42
Balance sheet & cash
Market cap₹1.4B
Free Cash Flow₹144.7M
Profitability & ownership
ROE12.4%
ROA6.8%
Last declaration on 4 December 2025
Declarations34 total
5,000 shares@ ₹89.07121.7% of flowEquity SharesSEBI:742ef9166bb323f37ce00d198ced95965defd690
Canonical exit: 3 Mar 2026 (T+90)
100,000 shares@ ₹224.212295.5% of flowEquity SharesSEBI:fded443b604da64783a94d854c8e542273643c65
2,886 shares@ ₹230.6222.8% of flowEquity SharesSEBI:c33fbbff6fcf270f4b4df3ef837d63cfb5364fe0
2,401,472 sharesEquity SharesSEBI:6028a527144e925b4e82f0e81b967f716d21c05e
1,000 shares@ ₹148.4496.8% of flowEquity SharesSEBI:65608814e90e0ace2b2f8097275a7650e263f1e0
Canonical exit: 7 Jun 2022 (T+90)
250 shares@ ₹149.944100.0% of flowEquity SharesSEBI:e65b94a264588f8105f4bcf53d6b5fa0432ca6f0
Canonical exit: 7 Jun 2022 (T+90)
2,000 shares@ ₹147.18528.2% of flowEquity SharesSEBI:85b5c3f3b1ebf96b42e999310fd61287ebcaa9c0
Canonical exit: 6 Jun 2022 (T+90)
1,000 shares@ ₹138.236.7% of flowEquity SharesSEBI:d5afe86ef5a33ade7f9327a7a8dd270da9877fec
Canonical exit: 5 Jun 2022 (T+90)
2,000 shares@ ₹141.513523.7% of flowEquity SharesSEBI:d7133505b38ecccc14f307d2209edc4db0a78189
Canonical exit: 5 Jun 2022 (T+90)
1,000 shares@ ₹147.43412.4% of flowEquity SharesSEBI:3d14084777cdd57b704a12bd98a4375de5028eb4
Canonical exit: 2 Jun 2022 (T+90)
3,000 shares@ ₹153.885738.7% of flowEquity SharesSEBI:e69e1506a588724420712372c3da145379f35509
Canonical exit: 31 May 2022 (T+90)
1,000 shares@ ₹152.6197.4% of flowEquity SharesSEBI:619526f8aa626ad886369901b6c4d2ef0c199b82
Canonical exit: 1 Jun 2022 (T+90)
2,000 shares@ ₹153.99614.0% of flowEquity SharesSEBI:995733101102e6aca068289df15b43bd1e3ace81
Canonical exit: 1 Jun 2022 (T+90)
2,000 shares@ ₹151.8825.2% of flowEquity SharesSEBI:9a7445b0ff5496b8a4568c901da3104dc20bb946
Canonical exit: 29 May 2022 (T+90)
1,000 shares@ ₹150.45714.3% of flowEquity SharesSEBI:de4e5ef767436d6f8ed8bf21f1f7fb2e7bc5184a
Canonical exit: 25 May 2022 (T+90)
1,000 shares@ ₹149.911100.0% of flowEquity SharesSEBI:10fee8ee31eb38587a44a1b14b90ffd8eee10ba0
Canonical exit: 23 May 2022 (T+90)
1,000 shares@ ₹149.91150.4% of flowEquity SharesSEBI:1cca5d85e491383dbca485f63a0690231f161816
Canonical exit: 23 May 2022 (T+90)
1,000 shares@ ₹143.006.5% of flowEquity SharesSEBI:db25bd1023c67af72a4dbdc2dc0d2def0e16d67b
Canonical exit: 23 May 2022 (T+90)
3,000 shares@ ₹152.133743.3% of flowEquity SharesSEBI:f88e34f7b21115ee3e4e79d7612740d74e2c9f2f
Canonical exit: 22 May 2022 (T+90)
1,000 shares@ ₹150.757.3% of flowEquity SharesSEBI:c811adf37330c13a077dea403578fb0891c9f86d
Canonical exit: 22 May 2022 (T+90)
1,000 shares@ ₹149.67849.6% of flowEquity SharesSEBI:9725f01e6c25c33b10ed286bc8e07b201eb632cc
Canonical exit: 16 May 2022 (T+90)
1,000 shares@ ₹150.93614.2% of flowEquity SharesSEBI:7789ecec225e4fc116df3a4366746ca92035beaa
Canonical exit: 16 May 2022 (T+90)
2,000 shares@ ₹156.32514.8% of flowEquity SharesSEBI:30ff183038b0fc42b9cdf5b5a9d06a69e1b1e509
Canonical exit: 15 May 2022 (T+90)
2,000 shares@ ₹152.98313.5% of flowEquity SharesSEBI:8c35ffd18ff3581df69eced26b4687c5026dedd5
Canonical exit: 15 May 2022 (T+90)
2,000 shares@ ₹187.267517.9% of flowEquity SharesSEBI:aea337734a10f71fb63b09e893025c31a3396aa1
Canonical exit: 20 Mar 2022 (T+90)
25 of 34 declarations
About Par Drugs And Chemicals Limited
Par Drugs And Chemicals Limited is a company engaged in the production of chemical and pharmaceutical products. It operates in the XBOM market.
